Showing results (81-90 of 347) with videos related to
Sort By:
Pageof 35
The Journal of Investigative Dermatology|August 20, 2003
Topical calcitriol is degraded by ultraviolet lightMark Lebwohl, John Quijije, Jean Gilliard, et al.Archives of Dermatological Research|November 26, 2022
Evaluating the research productivity of academic dermatologists based on the NIH-supported relative citation ratioCharles B Lau, Luka Machavariani, Guohai Zhou, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 10, 2006
Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effectsClark C Otley, Thomas Stasko, Whitney D Tope, et al.Journal of Drugs in Dermatology : JDD|October 6, 2023
Successful Treatment of Lichen Planus With Oral UpadacitinibMelissa P Zundell, Joshua Kaminetsky, Mark Lebwohl, et al.Cutis|August 1, 2008
A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatosesAnnemarie Uliasz, Joshua Zeichner, Jennifer Soung, et al.Journal of the American Academy of Dermatology|June 21, 2005
An extended 16-week course of alefacept in the treatment of chronic plaque psoriasisCarin H Gribetz, Robin Blum, Christopher Brady, et al.Journal of the American Academy of Dermatology|October 17, 2017
A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitisSherry H Yu, Aaron M Drucker, Mark Lebwohl, et al.Journal of Psoriasis and Psoriatic Arthritis|October 27, 2025
Real-world Evidence of Brodalumab Safety for the Treatment of PsoriasisMark Lebwohl, Eingun James Song, Tina Bhutani, et al.Archives of Dermatological Research|January 8, 2025
Evaluating the readability of FDA-approved JAK inhibitor medication guides in dermatologyWilliam C Lau, Charles B Lau, Vinod Nambudiri, et al.Journal of the American Academy of Dermatology|June 9, 2019
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trialLuis Puig, Mark Lebwohl, Hervé Bachelez, et al.Pageof 35